Ocean Biomedical, Inc. - Common Stock (OCEA)

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NASDAQ:OCEANASDAQOCEA)(NASDAQ:LVTXNASDAQLVTX,(NYSE:MRKNYSE),(NYSE:ABBVABBV) EQNX::TICKER_END

Several stocks are currently undergoing noteworthy developments, making them worthy of closer monitoring. This feature will delve into five stocks that merit inclusion in watch lists, offering insight into their potential.

On World Lung Cancer Day, Ocean Biomedical (NASDAQOCEA) shared details of its multipronged lung cancer program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. According to the announcement, Dr. Elias and his team have revealed that Chitinase 3-like-1 (“CHi3L1”) is a master regulator that inhibits antitumor immune responses. Ocean Biomedical’s lung cancer program is advancing several approaches to reversing immune system suppression caused by CHi3L1 alone and in combination with other immunotherapy pathways. The programs suppress primary and metastatic tumor growth in numerous animal models and hold potential use in multiple forms of visceral cancers. In recent studies, Ocean Biomedical’s programs have demonstrated up to 95% reduction in primary and metastatic tumor burden in lung cancer mouse models. “We are making discoveries that we believe will drive cancer research, and eventually treatment and patient outcomes, forward,” said Dr. Elias. “This pathway discovery is an unprecedented leap, because if you control CHi3L1, you don’t just control one anti-cancer pathway, you simultaneously control many anti-cancer pathways.”

PALM BEACH, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is one of the factors driving the need for the drugs used in the treatment. Moreover, the prevalence is significantly higher in the geriatric population compared to other types of cancers. Thus, an increase in the geriatric population is one factor driving the pancreatic cancer treatment market growth. The incidence is significantly higher in the geriatric population above 65 years of age compared to other types of cancers. A report from Fortune Business Insights said that: “the pancreatic cancer treatment market size is projected to grow to USD 6.85 billion by 2029, exhibiting a CAGR of 15.7% during 2022-2029. North America dominated the global market with a share of 46.97% in 2022. The increase in the number of patients suffering from the condition has increased the demand for the drugs used in treatment. These are some factors driving the growth during the forecast period. Companies engaged in manufacturing cancer drugs have increased their focus on R&D activities to develop new drugs for pancreatic cancer treatment. Additionally, the companies operating in the market have received approval from several regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the Medicines and Healthcare Products Regulatory Agency (MHRA) (U.K.), among others, thereby propelling the growth of the market. Moreover, new testing technologies are being adopted by hospitals and diagnostic centers to diagnose cancer. The increase in the diagnosis rates is driving the demand for drugs, thereby providing opportunities for the players.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), Ocean Biomedical, Inc. NASDAQ: OCEANASDAQOCEA)(NASDAQ: LVTXNASDAQLVTX, Merck & Co., Inc. (NYSE: MRKNYSE), AbbVie Inc. (NYSE: ABBVABBV).

On World Lung Cancer Day, Ocean Biomedical (NASDAQOCEA) shared details of its multipronged lung cancer program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. According to the announcement, Dr. Elias and his team have revealed that Chitinase 3-like-1 (“CHi3L1”) is a master regulator that inhibits antitumor immune responses. Ocean Biomedical’s lung cancer program is advancing several approaches to reversing immune system suppression caused by CHi3L1 alone and in combination with other immunotherapy pathways. The programs suppress primary and metastatic tumor growth in numerous animal models and hold potential use in multiple forms of visceral cancers. In recent studies, Ocean Biomedical’s programs have demonstrated up to 95% reduction in primary and metastatic tumor burden in lung cancer mouse models. “We are making discoveries that we believe will drive cancer research, and eventually treatment and patient outcomes, forward,” said Dr. Elias. “This pathway discovery is an unprecedented leap, because if you control CHi3L1, you don’t just control one anti-cancer pathway, you simultaneously control many anti-cancer pathways.”

Ocean Biomedical (NASDAQOCEA), a next-generation biopharma company working to accelerate the development and commercialization of compelling new biopharma discoveries, has been spotlighted in a recent Fundamental Research Corp. (“FRC”) report. The equity analyst report increased FRC’s price target of OCEA stock to $17.63 per share, up from its March 2023 of $16.40. According to the report, the uptick was based on several things, including Ocean Biomedical’s $25 million financing facility announced last month; the company being granted two new U.S. patents and one Brazilian patent for drug and vaccine candidates targeting malaria and cancer treatment; positive results from an independent study demonstrating that OCEA “antibodies can suppress glioblastoma (brain) tumor growth by 60%”; and the company’s plans to move forward with the manufacturing and IND-enabling studies needed to submit applications to the FDA to initiate human clinical trials and its diversified development pipeline. The FRC report also noted that the company has received 25 patents and has an additional 38 patent applications currently pending. “We are pleased to see our cumulative efforts and growing strengths recognized by Fundamental Research Corp.’s analyst coverage, especially the diverse potential of our core cancer, fibrosis, and infectious disease programs,” said Ocean Biomedical cofounder and executive chair Dr. Chirinjeev Kathuria in the press release.

Ocean Biomedical (NASDAQOCEA) is reporting that a broad U.S. patent has been issued to Dr. Jack A. Elias, MD, one of the company’s scientific cofounders. The patent is for bispecific antibodies targeting chitinase 3-like-1 (“CHi3L1”) and programmed cell death protein 1 (“PD-1”). The company called it “a promising new approach that has emerged from prior breakthrough discoveries that CHi3L1 is a ‘master regulator’ of tumor growth in multiple visceral cancers.” According to the announcement, the bispecific antibody is a cutting-edge immunotherapy approach that demonstrates significant potential by combining Ocean’s proprietary anti-CHi3L1 antibody with existing immune checkpoint inhibitors that target PD-1 in a bispecific-antibody format. The company reports that these bispecific antibodies “have been shown to synergistically kill tumor cells at levels dramatically exceeding the effectiveness of either the anti-CHi3L1 antibody or the anti-PD-1 antibody alone — in multiple cancer types and multiple animal models.”

Ocean Biomedical, Inc. (NASDAQOCEA) is engaged as a biopharmaceutical company, which is focused on the development and commercialization of

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NYSE:PFENYSEPFE)(NASDAQ:OCEANASDAQOCEA,(NYSE:NVSNYSE),(NASDAQ:RLAYRLAY) EQNX::TICKER_END

Ocean Biomedical, Inc. (NASDAQOCEA) is a Rhode Island-based biopharmaceutical company, which is focused on the development and commercialization of

Aesther, a special purpose acquisition company (“SPAC”) and Ocean Biomedical Inc. (NASDAQOCEA), a next-generation biopharma company, recently announced stockholder approval of all proposals related to the previously disclosed proposed business combination between Aesther and Ocean. According to the update, the approvals were secured at a special meeting of stockholders held on Feb. 3, 2023. The combined company, Ocean Biomedical, and its Class A common stock commenced trading on the Nasdaq Capital Market under the symbol OCEA. “I’m pleased that the majority of shareholders have, through their votes in favor of going public, reaffirmed their belief in our vision for the company,” said Dr. Chirinjeev Kathuria, Ocean Biomedical co-founder and executive chairman of the board of directors. “The business combination with Aesther brings us one step closer to realizing our foremost goals as an innovative life sciences company.”